• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Information Technology
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

The US Market for Rx to OTC Switches, Forecasts to 2019, 7th Edition

$1,995.00 – $3,995.00

Clear
SKU: KLI5459601 Categories: Over-the-Counter (OTC) Drugs, Pharmaceuticals Market Research, Prescription Drugs Market Reports Pages: 200
  • Description
  • Table of Contents
  • Latest reports

Description

The US Market for Rx to OTC Switches

Prescription products that are marketed as consumer products are known as Rx-to-OTC. They represent an important part of pharmaceutical strategy and a growing market. This report, The U.S. Market for Rx-to-OTC Switches focuses on several treatment segments in which Rx-to-OTC switches are available.

Patient-consumer awareness of health issues is driving the Rx-to-OTC market. Consumers are more prepared to take responsibility for their own health and are willing to purchase medicines over the counter. An increased focus on cost-savings, coupled with the effects of advertising and promotion, result a higher rate of OTC purchases. Elderly baby boomers, are taking greater interest in their health, and growing the Rx-to-OTC industry in America.

Segments profiled in the report include:

Smoking Cessation
Weight Loss
Gastrointestinal Drugs
Hair Loss Products
Hormones
Allergy
Analgesics, NSAIDs, and Pain Treatments
Anti-Infectives
Oral Care
Overactive Bladder
Rectal Ointments
Sleep-aids
Cough, Cold, and Sinus Products

In addition to the areas with switches in place, Kalorama Information has identified other areas which may be open to Rx-to-OTC switches in the future and are in development. These products are listed.

Present revenues and past revenues for segment markets consist of the switched brands and OTC drugs containing switched ingredients. Five year forecasts are provided.

In addition to this information, the study tracks current issues and trends affecting the industry and identifies trends that may arise in the future. Each segment provides an overview, descriptions of products on the market, market estimates and forecasts, and competitive analysis of leading providers.The report includes statistical information for conditions and diseases affecting the U.S. population, including detail discussions, tables and figures.

Table of Contents

EXECUTIVE SUMMARY

Overview

Scope and Methodology

Size and Growth of the Market

Issues and Trends Affecting the Rx-to-OTC Switches Market

Leading Participants

THE OTC DRUG INDUSTRY

Overview of the Over-the-Counter Drug Market

Distribution Channels

Retail Market ValueOTC Drug Industry

Development of the Rx-to-OTC Drug Market

U.S. Drug Regulation

Expanding Drug Access with Behind the Counter Status

Nonprescription Drug Safe Use Regulatory Expansion (NSURE)

Physician Uncertainty in Increasing Nonprescription Drug Access

Pharmacists Generally Favor Self-Medication

Online Resources for Health Information and Drug Selection

Social Media’s Influence on Consumer Health Products

U.S. Demographics and the Non-Prescription Drug Market

U.S. Population over 65

U.S. Health Spending Indicators

International Trends in Rx-to-OTC Switches

ALLERGY, COUGH, COLD, AND SINUS PRODUCTS

Overview

Antihistamines

Decongestants

Cough Preparations

Ophthalmic Preparations

Other Allergy Preparations

Mast Cell Stabilizers

Intranasal Steroids

Description of Conditions

Allergic Rhinitis

Common Cold

Sinusitis

Hives

Ocular Allergies

Product Analysis

Switched Products

Antihistamines

Decongestants

Cough Preparations

Ophthalmic Preparations

Other Allergy Preparations

Recent Switch Activity

Flonase Allergy

Nasacort Allergy

Prescription Products with Anticipated OTC Approvals

Astelin Nasal Spray

Beconase AQ

Rhinocort

Clarinex

Xyzal

Atrovent Nasal Spray

Nasonex

Singulair

Market Analysis

Market Size and Forecast

Competitive Analysis

ANALGESICS AND OTHER PAIN RELIEVERS

Overview

Analgesics

Nonsteroidal Anti-inflammatory Drugs

Topical Pain Relievers and Other Similar Products

Description of Conditions

Pain

Inflammation

Product Analysis

Switched Products

Antipruritic

Internal analgesic/antipyretic

Oral Anesthetic

Prescription Products with Anticipated OTC Approvals

Nonsteroidal anti-inflammatory drugs

Voltaren (diclofenac)

Diflunisal

Etodolac

Nabumetone

Feldene (piroxicam)

Migraine Treatments

Axert

Imitrex

Maxalt

Zomig

Other Migraine Treatments

Market Analysis

Market Size and Forecast

Competitive Analysis

ANTI-INFECTIVES

Overview

Antibiotics

Antifungals

Antivirals

Antiparasitics

Description of Conditions

Vaginal Infections

Athlete’s Foot

Jock Itch

Ringworm

Dandruff

Scabies and Pediculosis

Pinworm

Fungal Nail Infections

Product Analysis

Switched Products

Antifungals

Anthelmintics

Antimicrobials

Pediculicides

Prescription Products with Anticipated OTC Approvals

Antivirals

Zovirax

Valtrex

Denavir

Famvir

Influenza Antivirals

Antibiotics

Antibiotic Public Health Preparedness

Antifungals

Market Analysis

Market Size and Forecast

Competitive Analysis

GASTROINTESTINAL DRUGS

Overview

Description of Conditions

Nausea

Diarrhea

Constipation

Heartburn

Acid reflux

Product Analysis

Switched Products

Histamine H2 Inhibitors

Proton Pump Inhibitors

Antidiarrheals

Laxatives

Antiemetics

Recent Switch Activity

Prescription Products with Anticipated OTC Approvals

Proton Pump Inhibitors

Protonix

Aciphex

Mucosal Protectants

Antiemetics

Market and Competitive Analysis

Market Size and Forecast

Competitive Analysis

SMOKING CESSATION PRODUCTS

Overview

Description of Conditions

Lung Cancer and Tobacco Use

Product Analysis

Switched Products

Nicotine Chewing Gum

Nicotine Transdermal patch

Nicotine Oral lozenge

Prescription Products with Anticipated OTC Approvals

Nicotrol

Chantix

Market Analysis

Market Size and Forecast

Competitive Analysis

OTHER DRUG CLASSIFICATIONS

Overview

Contraceptives

Dental Rinses and Fluorides

Hair Growth Products

Rectal Ointments

Sleep Aids

Weight Management

Description of Conditions

Pregnancy

Abortion Rates

Contraceptive Use

Dental carries

Hereditary Hair Loss

Hemorrhoids

Sleeplessness

Obesity

Urinary Incontinence/Overactive Bladder

Conditions with Possible Future OTC Treatments

Acne Vulgaris

Benign Prostate Hypertrophy (BPH)

Elevated Cholesterol

Erectile Dysfunction

Menopause and Hormone Replacement

Menorrhagia

Osteoporosis

Product Analysis

Switched Ingredients

Contraceptives

Dental rinses and fluoride

Hair growth

Overactive Bladder

Rectal ointments

Sleep aids

Weight Management

Prescription Products with Anticipated OTC Approvals

Acne Treatments

Cholesterol-reducing Drugs (antilipidemics)

Blood Products

BPH

Erectile Dysfunction

Hair Loss Treatment

Hormone-Replacement Therapies (HRT)

Osteoporosis Treatments

Opioid Overdose Treatment

Overactive Bladder

Sleep Aids

Market Analysis

Current Market Segments

Short-Term New Product Segment Development; 2015-2016

Antilipidemics

Opioid Overdose Treatment

Sexual Dysfunction

New Product Segments; Post 2016

BPH Treatments

Hormone Replacement Therapy and Osteoporosis Treatments

Competitive Analysis

TOTAL RX-TO-OTC DRUG MARKET SUMMARY

Overview

Total market Size and Forecast

Switch Forecast in the United States

Markets by Segments

Competitive Analysis

PROFILES FOR MAJOR RX-TO-OTC PARTICIPANTS

Introduction

Strategies for Continued Product Growth

Mergers and Acquisitions

GlaxoSmithKline and Novartis AG

Bayer AG and Merck & Co.

Prestige Brands and Insight Pharmaceuticals

Perrigo Company Acquisitions

Procter & Gamble and Teva Pharmaceutical Industries

Sanofi and Chattem Consumer

Schering-Plough and Merck & Co.

Wyeth and Pfizer

Reckitt Benckiser and Adams Respiratory Therapeutics

Simultaneous Marketing – Prescription vs OTC

Impact on the Prescription Drug Manufacturer

Direct-to-Consumer Advertising

Patent Expiration

Bayer

Boehringer Ingelheim

GlaxoSmithKline

Johnson & Johnson

Novartis

Perrigo Company

Pfizer

Prestige Brands

Procter & Gamble

Reckitt Benckiser

Sanofi/Chattem

TEVA

COMPANY DIRECTORY

LIST OF EXHIBITS

EXECUTIVE SUMMARY

Table 1-1

The U.S. Market for Rx-to-OTC Switches 2009-2019

Figure 1-1

The U.S. Market for Rx-to-OTC Switches, 2009-2019

THE OTC DRUG INDUSTRY

Table 2-1

Number of Retail Establishments in the United States and Non-Prescription Medicine

Availability, 2012

Table 2-2

OTC Drug Retail Sales*, 2000-2014

Figure 2-1

OTC Retail Sales, 2000-2014

Table 2-3

Rx-to-OTC Switches Approved by the FDA 1976–2014

Table 2-3 (continued)

Rx-to-OTC Switches Approved by the FDA 1976–2014

Figure 2-2

Number of New Rx-to-OTC Switches in the United States, per Year 1976-2014

Table 2-4

Statistics for Selected Rx-to-OTC Switches (United States)

Table 2-5

Estimated OTC Sales by Product Type and Percent of Sales Attributed to Rx-to-OTC

Switched Ingredients

Figure 2-3

Estimated OTC Sales by Product Type and Percent of Sales Attributed to Rx-to-OTC

Switched Ingredients

Figure 2-4

Typical Pharmacist-Consumer OTC Drug Counseling Session

Figure 2-5

Internet Users, Percent of Total Population, 2014

Table 2-6

The U.S. Population, 1980-2050

Figure 2-6

The U.S. Population, 1980-2050

Table 2-7

Percent U.S. Population Over Age 65 by Year, 2000-2050

Figure 2-7

United States Population Trend Age 65+, 2000-2050

Table 2-8

U.S. Healthcare Industry Inflation Rates Healthcare Industry Consumer Price Index

Comparisons 2000-2014 Data

Figure 2-8

U.S. Healthcare Industry Inflation Rates Healthcare Industry Consumer Price Index

Comparisons 2000-2010

Table 2-9

Legal Classification Status of Selected Ingredients Worldwide

Table 2-9 (continued)

Legal Classification Status of Selected Ingredients Worldwide (continued)

Table 2-9 (continued)

Legal Classification Status of Selected Ingredients Worldwide (continued)

Table 2-10

Individual Ingredients Switched from Rx to OTC by Country, 2013/2014

ALLERGY, COUGH, COLD, AND SINUS PRODUCTS

Figure 3-1

U.S. Incidence of Allergy, Cough, Cold, Sinus Conditions, Superimposed on Total

Population, 2014 Estimate

Table 3-1

Allergy, Cough, Cold, Sinus Product Ingredients Transferred from Rx-to-OTC Status. 54

Table 3-1 (continued)

Allergy, Cough, Cold, Sinus Product Ingredients Transferred from Rx-to-OTC Status. 55

Figure 3-2

Allergy, Cough, Cold, Sinus Product Ingredients Transferred from Rx-to-OTC by Year56

Table 3-2

Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name,

Distributor and Current Activity

Table 3-3

The U.S. Market for Rx-to-OTC Switches Allergy, Cough, Cold, and Sinus Product

Revenues 2009-2019

Figure 3-3

The U.S. Market for Rx-to-OTC Switches Allergy, Cough, Cold, and Sinus Product

Revenues 2009-2019

Figure 3-4

The U.S. Market for Rx-to-OTC Switches: Allergy, Cough, Cold, and Sinus Products,

by Percent and Product Type, 2014

Figure 3-5

U.S. Market for Rx-to-OTC Switches: Allergy, Cough, Cold, Sinus, Value Switched

Brands vs. Switched Equivalents (Generics), 2009-2019

Table 3-4

Leading Suppliers’ Shares for U.S. Market for Rx-to-OTC Switches: Allergy, Cough,

Cold, and Sinus Products, 2014

Figure 3-6

Leading Suppliers’ Shares for U.S. Market for Rx-to-OTC Switches: Allergy, Cough,

Cold, and Sinus Products, 2014

ANALGESICS AND OTHER PAIN RELIEVERS

Figure 4-1

U.S. Incidence of Conditions with Pain and Inflammatory Symptoms Superimposed on

Total Population, 2014 Estimates

Table 4-1

Analgesics, NSAIDs and Other Ingredients Transferred from Rx-to-OTC Status

Figure 4-2

Analgesics, NSAIDs and Other Ingredients Transferred from Rx-to-OTC by Year

Table 4-2

Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name,

Distributor and Current Activity

Table 4-3

The U.S. Market for Rx-to-OTC Switches Analgesic Product Revenues 2009-2019

Figure 4-3

The U.S. Market for Rx-to-OTC Switches Analgesic Product Revenues 2009-2019

Figure 4-4

The U.S. Market for Rx-to-OTC Switches: Analgesic Product Percent by Type, 2014 93

Table 4-4

Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches Analgesics

2014

Figure 4-6

Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches Analgesics

2014

ANTI-INFECTIVES

Figure 5-1

U.S. Incidence of Infections by Type Superimposed on Total Population, 2014

Estimates

Table 5-1

Anti-infectives Ingredients Transferred from Rx-to-OTC Status

Figure 5-2

Anti-infectives Ingredients Transferred from Rx-to-OTC by Year

Table 5-2

Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name,

Distributor and Current Activity

Table 5-3

The U.S. Market for Rx-to-OTC Switches Anti-infective Product Revenues 2009-2019116

Figure 5-3

The U.S. Market for Rx-to-OTC Switches Anti-infective Product Revenues 2009-2019117

Figure 5-4

The U.S. Market for Rx-to-OTC Switches: Anti-infective Product Type, 2014

Table 5-4

Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switched Anti-infectives

2014

Figure 5-6

Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switched Anti-infectives

2014

GASTROINTESTINAL DRUGS

Figure 6-1

U.S. Incidence of Gastrointestinal Conditions and Disorders Superimposed on Total

Population, 2014 Estimate

Table 6-1

Gastrointestinal Drug Ingredients Transferred from Rx-to-OTC Status

Figure 6-2

Gastrointestinal Drug Ingredients Transferred from Rx-to-OTC by Year

Table 6-2

Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name,

Distributor and Current Activity

Table 6-3

The U.S. Market for Rx-to-OTC Switches Gastrointestinal Drug Revenues 2009-2019139

Figure 6-3

The U.S. Market for Rx-to-OTC Switches Gastrointestinal Drug Revenues 2009-2019140

Figure 6-4

The U.S. Market for Rx-to-OTC Switches: Gastrointestinal Drug by Product Type, 2014141

Table 6-4

Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches Gastrointestinal

Drugs 2014

Figure 6-6

Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches Gastrointestinal

Drugs 2014

SMOKING CESSATION PRODUCTS

Table 7-1

Smoking Cessation Product Ingredients Transferred from Rx-to-OTC Status

Figure 7-1

Smoking Cessation Product Ingredients Transferred from Rx-to-OTC by Year

Table 7-2

Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name,

Distributor and Current Activity

Table 7-3

The U.S. Market for Rx-to-OTC Switches Smoking Cessation Product Revenues 2009-

2019

Figure 7-2

The U.S. Market for Rx-to-OTC Switches Smoking Cessation Product Revenues 2009-

2019

Figure 7-3

The U.S. Market for Rx-to-OTC Switches: Smoking Cessation Product Type, 2014 . 160

Table 7-4

Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches Smoking

Cessation Drugs 2014

Figure 7-5

Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches Smoking

Cessation Drugs 2014

OTHER DRUG CLASSIFICATIONS

Table 8-1

U.S. Crude Birth Rate per 1,000 Persons 2000, 2005, 2010 and Projected 2015 and 2020170

Table 8-2

Miscellaneous Drug Ingredients Transferred from Rx-to-OTC Status by Trade Name,

Distributor, and Date of OTC Approval

Figure 8-1

Miscellaneous Drug Ingredients Transferred from Rx-to-OTC by Year

Table 8-3

Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name,

Distributor and Current Activity

Table 8-3 (continued)

Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name,

Distributor and Current Activity

Table 8-4

The U.S. Market for Rx-to-OTC Switches Other Drug Classification Product Revenues

2009-2019

Figure 8-2

The U.S. Market for Rx-to-OTC Switches Other Drug Classification Product Revenues

2009-2019

Figure 8-3

The U.S. Market for Rx-to-OTC Switches Other Drug Classifications Distribution of

Revenues by Product Type 2014

Figure 8-4

The U.S. Market for Rx-to-OTC Switches Other Drug Classifications Distribution of

Revenues by Product Type 2019

TOTAL RX-TO-OTC DRUG MARKET SUMMARY

Table 9-1

The U.S. Market for Rx-to-OTC Switches 2009-2019

Figure 9-1

The U.S. Market for Rx-to-OTC Switches, 2009-2019

Table 9-2

Potential Rx-to-OTC Switches, 2015-2019

Table 9-2 (continued)

Potential Rx-to-OTC Switches, 2015-2019

Table 9-2 (continued)

Potential Rx-to-OTC Switches, 2015-2019

Table 9-3

The U.S. Market for Rx-to-OTC Switches 2009-2019

Figure 9-2

The U.S. Market for Rx-to-OTC Switches by Product Category, 2009-2019

Figure 9-3

The U.S. Market for Rx-to-OTC Switches, Distribution of Revenues by Product

Category 2014

Figure 9-4

The U.S. Market for Rx-to-OTC Switches, Distribution of Revenues by Product

Category 2019

Table 9-4

Leading Suppliers Significant Segments of Participation within the U.S. Market for Rxto-

OTC Switches, 2014

Figure 9-5

Leading Suppliers Market Share in the U.S. Market for Rx-to-OTC Switches, 2014 .. 229

PROFILES FOR MAJOR RX-TO-OTC PARTICIPANTS

COMPANY DIRECTORY

 

    The Market for Rx-to-OTC Switches, 8th Edition
    May 5, 2022
    Global Over-the-Counter (OTC) Drug Markets
    January 23, 2018
    The US Market for Rx to OTC Switches, Forecasts to 2019, 7th Edition
    February 2, 2015
    The U.S. Market for Rx to OTC Switches, 6th Edition
    January 11, 2013

Related products

  • Placeholder image

    Worldwide Market for Prescription Dermatological Drugs – 4th Edition, The

    $3,500.00 – $7,000.00
  • Placeholder image

    Emerging Cancer Vaccine Market, The

    $3,500.00 – $7,000.00
  • Placeholder image

    Men’s Health: The World Market for Current and Emerging Drug Therapies

    $2,625.00 – $5,250.00
  • Placeholder image

    Rheumatoid Arthritis: The 45 Market in the United States for Drugs and Biologics

    $2,246.00 – $4,492.00

Contact Us

  • 671 North Glebe Road, Suite 1610 Arlington, VA 22203 United States

  • Email Us

  • 703-778-3080

  • Send us a message!

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • 4 Fascinating Facts About Cancer Diagnostics March 4, 2025
  • Food Animal Diagnostics Market: Spotlight on Disease Testing Amid Bird Flu Surge February 20, 2025
  • Custom Competitive Intelligence (CI) Research: A New Strategic Imperative For Lab Diagnostics Companies  February 19, 2025
  • The Rise of Pharmacodiagnostics in the $10 Billion Global Cancer Diagnostics Market February 1, 2025
  • IVD Trends to Watch: Personalized Medicine Adds Precision to Diagnostic Testing January 2, 2025

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement
  • Privacy Settings

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
The Market for In Vitro Diagnostic Tests in Latin America: Forecasts to 2019...Global Orthopedic Device Market (Hip, Knee, Spine, Extremities and Trauma D...
Scroll to top